Clinical Trial Update: Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Indium-111 pentetreotide in patients with refractory cancer across multiple tumor types. The study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain and Central Nervous System Tumors
• Childhood Langerhans Cell Histiocytosis
• Gastrointestinal Carcinoid Tumor
• Head and Neck Cancer
• Intraocular Melanoma
• Islet Cell Tumor
• Lung Cancer
• Melanoma

Drugs mentioned

• Indium-111 pentetreotide (Indium-111 pentetreotide)

Snippet

Sponsor: Yale University | Conditions: Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis | Phase 1 | Status: TERMINATED